At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 285 enrolled
Drug / intervention
CP-690,550 Eye drops +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Prospective, Randomized, Double Masked/Investigator Masked, Vehicle And Comparator (Sodium Hyaluronate Eye Drops) Controlled, Dose Ranging Study Of CP-690,550 Eye Drops In Subjects With Dry Eye Disease
In Brief
A Phase 2 clinical trial evaluating CP-690,550 Eye drops, CP-690,550 Eye drops-vehicle, and 1 other intervention for Dry Eye Syndromes. Completed, enrolled 285 participants across 28 sites in 2 countries.
Detailed Summary
The purpose of the study is to evaluate dose-response, efficacy and safety of CP-690,550 eye drops in patients with dry eye disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes
CountriesJapan, South Korea
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartJul 2010
Primary CompletionApr 2011
TodayJul 2026
First PostedJun 2, 2010
Enrollment StartJul 1, 2010
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.1 years ago
Interventions
CP-690,550 Eye dropsdrug
Ophthalmic topical solution, low dose, dosed once/day, 8 weeks
CP-690,550 Eye dropsdrug
Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
CP-690,550 Eye dropsdrug
Ophthalmic topical solution, high dose, dosed once/day, 8 weeks
CP-690,550 Eye drops-vehicledrug
Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks
Sodium Hyaluronatedrug
Ophthalmic topical solution, dosed 6 times/day, 8 weeks